Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Anticancer Res. 2020 Jun;40(6):3345-3354. doi: 10.21873/anticanres.14317.
BACKGROUND/AIM: In addition to its cytocidal effects as a microtubule dynamics inhibitor, eribulin mesylate (eribulin) regulates the tumour microenvironment. We examined the clinical significance of tumour infiltrating lymphocytes (TILs) and transforming growth factor-β (TGF-β), which are local markers of host immunity, and of the neutrophil-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC), which are systemic markers.
We administered eribulin chemotherapy to 106 patients with locally advanced or metastatic breast cancer. Of these, 21 had their lesions resected.
The response to eribulin was significantly associated with ALC (p=0.007). The expression of pSmad2 (an indicator of activation of TGF-β downstream signaling) was significantly decreased before and after eribulin chemotherapy (p<0.001). Moreover, a baseline ALC ≥ 1,500 /μl was observed in a significantly high number of patients with pSmad2 negative conversion (p<0.001).
Eribulin improved the tumour immune microenvironment by decreasing TGF-β expression. This demonstrated that local change can be evaluated based on ALC.
背景/目的：除了作为微管动力学抑制剂的细胞毒性作用外，甲磺酸艾日布林还能调节肿瘤微环境。我们研究了肿瘤浸润淋巴细胞（TILs）和转化生长因子-β（TGF-β）的临床意义，这两个指标是宿主免疫的局部标志物，中性粒细胞与淋巴细胞比值（NLR）和绝对淋巴细胞计数（ALC）是全身标志物。
我们对 106 名局部晚期或转移性乳腺癌患者给予艾日布林化疗，其中 21 名患者的病灶接受了切除术。
艾日布林的疗效与 ALC 显著相关（p=0.007）。pSmad2（TGF-β下游信号激活的指标）的表达在艾日布林化疗前后显著降低（p<0.001）。此外，基线时 ALC≥1500/μl 的患者中，pSmad2 阴性转化率明显更高（p<0.001）。
艾日布林通过降低 TGF-β 的表达来改善肿瘤免疫微环境。这表明可以根据 ALC 来评估局部变化。
